KCC2 as a novel biomarker and therapeutic target for motoneuron degenerative disease
C. Sahara Khademullah, Julien Bourbonnais, Mathilde Chaineau, María José Castellanos‐Montiel, Iason Keramidis, Alexandra Legault, Marie-Ève Paquet, Agessandro Abrahão, Lorne H. Zinman, Janice Robertson, Thomas M. Durcan, Melanie A. Woodin, Antoine G. Godin, Yves De Koninck
This study identifies KCC2 as an early biomarker and therapeutic target for ALS by showing its downregulation in motor neurons and the ability of KCC2-enhancing compounds to delay disease progression.
bioRxiv · Aug 24, 2023 · PreprintNeuroscience